Short answer
IDEAYA Biosciences, Inc. (IDYA) filed an 8-K current report with the SEC on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results for the quarter ended September 30, 2026 announced.
IDEAYA Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results for the quarter ended September 30, 2026 announced
- Full earnings release furnished as Exhibit 99.1, containing the detailed results and management update
- Results announcement provides investors a scheduled review of IDEAYA’s cash position, clinical pipeline and operating performance
Item EX-99.1 · Exhibit EX-99.1
- Q3 2026 NDA submitted for darovasertib plus crizotinib in metastatic uveal melanoma, creating a potential near-term regulatory catalyst
- OptimUM-010 Phase 3 enrollment stopped, with estimated cost savings of $100-125 million redirected toward IDE849 and IDE892
- IDE849 data showed 17.4-month median overall survival in 2L SCLC and 36.8% confirmed response rate in NEC
- Cash, equivalents and marketable securities totaled $1.15 billion, supporting runway into 2030 despite $125.7 million quarterly net loss
- Q3 collaboration revenue rose to $10.2 million, while R&D expense increased to $121.6 million and G&A to $26.3 million
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other IDEAYA Biosciences, Inc. 8-K filings
Get the next IDYA 8-K as it lands
Follow IDYA for push alerts, or ask the research agent what this filing means.